Meet Commander Reid Wiseman, the responsible for the success of the Artemis II mission once it launches. Photo courtesy of NASA

The world now knows the names of the four Houston-based astronauts who will launch in the first crewed moon mission in 50 years. NASA's Artemis II will see the first woman and person of color helming a lunar voyage, a first since the agency's history.

Astronaut Christina Hammock Koch, herself part of a history-making astronaut class and first all-female spacewalk— will join Victor Glover — the first person of color heading to the moon. Rookie Canadian astronaut Jeremy Hansen rounds out the crew with Commander Reid Wiseman.

Building on the unmanned Artemis I mission to the moon that concluded in December, Artemis II is slated to launch around November 2024, per NASA. In a scene familiar to space fans, the Artemis II crew will deploy inside the cozy Orion spacecraft that will sit atop the Space Launch System (SLS) rocket from Kennedy Space Center in Florida.

Artemis II's crew will spend some 10 days in orbit and even venture farther than the 1.4 million miles logged by Artemis I, adding to the historic nature of the journey. After moon orbit, the spacecraft will return to Earth for splashdown and recovery — always a celebrated moment after the highly anticipated takeoff.

Data gathered from Artemis II will pad information from Artemis I in effort to create a permanent moon outpost. On the moon, crews will learn how to live and work away from Earth, which will pave the way for the eventual mission to Mars. A planned Artemis III mission may launch in 2025 or '26, per NASA, which picks up from the last trip, Apollo 17 in 1972. The Artemis III mission, NASA promises, will see the first woman and person of color on the moon.

CultureMap caught up with a very busy Wiseman, who is now responsible for the success of the Artemis II mission once it launches. Hailing from Baltimore, Maryland, the 47-year-old earned his master's degree from Johns Hopkins University and is a decorated naval aviator, serving in the Middle East as a fighter pilot. The Artemis II mission commander completed a 165-day trip to the International Space Station in 2014 and was most recently chief of the astronaut office, per his bio. He has two sons with wife Carol, who passed away from cancer in May 2020.

The Artemis II crew was announced earlier this week. Photo courtesy of NASA

CultureMap: Congratulations, Commander. As Artemis II's leader, you are joining lunar mission commander names like the first man on the moon, Neil Armstrong, and Apollo 13's Jim Lovell. Do you allow yourself to think like that?

Reid Wiseman: Thank you. I do not allow myself to think like that. I think if you get to meet this crew — Victor Glover, Christina Koch, Jeremy Hanson — I really think we would say we want this to be so routine. We want Artemis II to be so successful and so long term that people completely forget about us. We're just that initial little stepping stone. I really hope that's the case. I am flying with an incredible group of heroes and I can't wait to go get this job done.

CM: What does it mean, as mission commander, to have the safety — and the lives — of these amazing and history-making astronauts in your hands once you launch?

RW: It means everything to me.

CM: You and the crew are so incredibly accomplished in your own individual spaces. Yet when you get to NASA — as Christina Koch once told me — you're kind of learning anew. What are you learning now?

RW: When you look at our crew, our next step is to learn about the spacecraft that will be operating in deep space. It's a very capable, very redundant, robust machine. So we have to get in the classroom, we've got to learn about all the capabilities, but we also have to get out and see the workforce.

We'll be the first humans to ever ride on this vehicle. And there's a lot of unknowns. We have a lot of systems to test. Uh One was very successful.

We need to hit the books and then we need to get in the sim [simulator], we need to practice simulations, learn how we all operate together as a team and then learn about the failure modes of the vehicle, how we can work around to keep ourselves safe and keep the mission going. And then after that, I think we'll be ready to look at Florida — and head out to the moon.

CM: Do prior lunar flight commanders and icons — like Armstrong and Lovell — serve as role models? How about the astronaut network in general?

RW: I think we look at those legends as their heroes, but they are also friends. Those folks really gave their lives to our nation and when they landed on the moon for the first time. But the amazing part for us as younger astronauts is they're still heavily engaged in everything we do right now.

I talked to Jack [Harrrison] Schmitt just a few months ago. Dave Scott still comes by every time he can to talk about geologic processes on the moon. Like these guys are our friends. It's really, really neat.

Neil Armstrong was amazing. John Young was incredible — he led our office for a number of years. Those guys are heroes to us for sure. When you look at who has taught me the most about being an astronaut, it's the folks I flew with on my first mission. It's the folks that I've worked with in the astronaut office. Now, I've seen some exceptional examples of leadership and followership and both skills are critical to be an astronaut.

CM: You learned you'll be headed to the moon — the dream adventure of billions all over the world— in the most office kind of way, we hear.

RW: Uh yeah, we all goofed up [laughs]. We missed the meeting. The chief astronaut put a placeholder on my schedule for a different topic. I was actually at a doctor's office and the doctor just walked in. So, I missed the first part of the meeting and I was able to use Microsoft Teams and dial in towards the end.

When the camera popped up, I saw the chief astronaut — who I expected to see for my meeting. But then, I also saw Norm Knight, our director of flight operations. I also saw Victor Glover and Christina Koch. And I was like, ‘oh boy, I think I just missed something big here.’

CM: Well, we've all missed meetings. But this was big — like headed to the moon big.

RW: Right [laughs]. It turned out that both Christina and Victor also missed the beginning of the meeting. So, we all showed up in perfect harmony.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.